




































Breast cancer is the most prevalent women’s cancer 
worldwide [1].
  Although the rate of breast cancer in the 
United States, 122.9 per 100,000 U.S. women [2], is 
among the highest in the world [3], certain regions, 
including the northeastern states, have somewhat higher 
rates than the US overall. In particular, Suffolk County 
and Nassau County, Long Island (LI), New York (NY), 
with rates of 142.7 and 138.7 per 100,000 women from 
2000-2004 [4] respectively, have been the focus of 
several studies looking for associations between 
environmental pollutants and breast cancer [5]. An 
increased risk of breast cancer was associated with 
home pesticide use [6], and residence within 1 mile of 
hazardous waste sites containing organochlorine [7]. 
Gammon [8] reported increased risk, without dose 






































adducts in DNA of circulating mononuclear cells, a 
measure of relatively recent exposure. A LI hospital-
based study found no increased risk of breast cancer 
associated with organochlorine concentrations in breast 
adipose tissue [9] and Jacquez [10] found no association 
between airborne cadmium exposure and breast cancer 
rates on LI. 
 
In 2006, McElroy [11] reported in a population based 
study that non-occupationally exposed Wisconsin 
women in the highest quartile of urinary cadmium 
(≥0.58 μg/g of creatinine), had twice the breast cancer 
risk compared to women in the lowest quartile (<0.26 
ug/g) after adjustment for risk factors. Cadmium, a 
known carcinogen and risk factor for lung cancer 
[12,13], accumulates in the human body with age 
[14,15], and has several unique properties, including 
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 and inhibition of DNA repair [19-22], which are 
potential risk factors for breast cancer carcinogenesis.  
Recently, Benbrahim-Tallaa [23] showed that cadmium  
directly transforms an estrogen receptor negative human 
breast cancer cell line incapable of xenograft formation 
to a basal-like breast cancer phenotype, which grows 
readily as a xenograft. 
 
In humans, cadmium has an elimination half-life of 12 
to 30 years [12, 24]. Cadmium is unique among the 
common heavy metal pollutants in that urinary 
cadmium is a biomarker of lifetime exposure, providing 
a means for assessing total body burden of 
cadmium[14,15]. Women tend to have higher cadmium 
levels than men presumably because of lower iron 
stores, which increase  cadmium absorption [25, 26].   
Thus, comparable environmental exposures to cadmium 
may disproportionately affect women compared to men 
[25].  
 
Because of the relatively high incidence of breast cancer 
on LI, we looked for associations between urine 
cadmium and breast cancer in a case-control sample of 
women living on LI obtained from the Long Island 
Database Project for Breast Cancer (LIDPBC),  a reposi-
tory of demographic and health data of female residents 
of LI.  The results were compared to a cross-sectional 
U.S. probability sample, the National Health and 





In weighted, unadjusted, logistic regression analyses, 
log-transformed UCd, menopause, and continuous age 
in years were significantly associated with increased 
risk of breast cancer in both the NHANES (Table 1) 
and LIDPBC (Table 2) samples. The categorical 
variables for UCd quartile and age were significantly 
associated with increased risk of breast cancer in both 
samples. A dichotomous variable for below/above 
median UCd for LIDPBC controls was also 
significantly associated with increased breast cancer 
risk in the LIDPBC sample.  Non-Hispanic white race 
was significantly associated with breast cancer in the 
NHANES sample. Smoking was significantly 
associated with breast cancer in the LIDPBC sample 
but not in the NHANES sample, and drinking was not 
significantly associated with breast cancer in either 
sample. Hormone use and later-/nulli-parity were not 
significantly associated with increased breast cancer 
risk in unadjusted analyses of either sample. LIDPBC 
cases had a statistically significant higher geometric 
mean of 0.58 μg cadmium/gram creatinine (μg/g) (me- 
dian, 0.59) compared to 0.41 μg/g (median, 0.45) for 
controls. LIDPBC cases were older (63 years) than the 
controls (59 years) and fewer of the LIDPBC cases 
(43%) never smoked compared to LIDPBC controls 
(59%). 
 
 In a weighted, unadjusted, logistic regression model 
(Table 3), women in the highest cadmium quartile 
showed greater risk for breast cancer relative to those 
in the lowest cadmium quartile for both LIDPBC 
(OR=3.54; 95% CI=1.49, 8.42; p=0.004) and 
NHANES (OR=3.39; 95% CI=1.64, 7.05; p=0.001).   
Women in the third highest quartile showed 
significantly elevated odds for breast cancer in the 
NHANES sample (3.84; 95% CI=1.95, 7.55; p<0.001) 
and borderline association in the LIDPBC sample 
(OR=2.27; 95% CI=0.97, 5.33; p=0.060). The p value 
for trend of increasing risk with increasing urine 
cadmium quartile was significant for both samples. 
Age-adjustment attenuated this association but the 
trends for increased odds of breast cancer across 
increasing UCd quartiles remained statistically 
significant in both samples. 
 
In a common, multivariable-adjusted model (Table 3) 
(adjusted for age group, smoking, drinking and 
menopausal status) for the NHANES sample, odds for 
breast cancer were significant and elevated for the 
third UCd quartile (OR=2.50; 95% CI=1.11, 5.63; 
p=0.028) and marginally significant for the fourth 
quartile (OR=2.22; 95% CI=0.89, 5.52; p=0.086). In 
the common LIDPBC model, the fourth quartile 
showed elevated odds for breast cancer relative to the 
lowest quartile (OR=2.69; 95% CI=1.07, 6.78; 
p=0.036).  The trend for increased odds of breast 
cancer was significant across increasing UCd quartiles 
for NHANES (p=0.039) and LIDPBC (p=0.023). 
Adjustment for race/ethnicity in the NHANES model 
and for family history of breast cancer in the LIDPBC 
model did not alter these findings.  
 
The LI never-smoker cases (n=43) and never-smoker 
controls (n=58) had significantly higher UCd, 0.53 
ug/g and 0.46 ug/g, respectively, than the NHANES 
never-smoker cases (n=55), 0.38 ug/g and the 
NHANES never-smoker controls (n=1885), 0.33 ug/g 
(p=0.011 and 0.002, respectively). When smokers are 
included, the LI cases (n=100) also had a significantly 
higher median UCd, 0.59 ug/g, compared to the 
NHANES cases (n=99), 0.45 ug/g (p=0.003), whereas 
the median UCd of the LI controls (0.45 ug/g, n=98) 
was not significantly higher than the NHANES 
controls (0.39 ug/g, n=3120) (p=0.224). 
 
   





























































































































UCd (μg/g) Median  0.45 0.39 0.39 
- 
UCd Quartile




   Q1: UCd<0.22 
(reference group) 
10 (10%)  694 (22%)  704 (22%) 
   Q2: 0.22≤UCd<0.37  24 (24%)  776 (25%)  800 (25%) 
   Q3: 0.37≤UCd<0.60  34 (34%)  799 (26%)  833 (26%) 
   Q4: UCd≥0.60  31 (31%)  851 (27%)  882 (27%) 
Age (years) 











Age group # (%):     
 
<0.001 
   30≤years<55 
(reference group) 
21 (21%)  1,671 (54%)  1,692 (53%) 
   55≤years<69  31 (31%)  733 (23%)  764 (24%) 
   69 years and older  47 (47%)  716 (23%)  763 (24%) 
Never-smokers 





















































































































































































































UCd (μg/g) Median  0.59
b 0.45 0.52 
- 
UCd Quartile
c # (%): 




   Q1: UCd<0.22  11 (11%)  23 (23%)  34 (17%) 
   Q2: 0.22≤UCd<0.37  7 (7%)  14 (14%)  21 (11%) 
   Q3: 0.37≤UCd<0.60  38 (38%)  35 (36%)  73 (37%) 
   Q4: UCd≥0.60  44 (44%)  26 (27%)  70 (35%) 
LIDPBC UCd  below and above 
control median
d # (%) 




  Below median (UCd≤0.40)  32 (32)  51 (52)  83 (42) 
   Above median (UCd>0.40)  68 (68)  47 (48)  115 (58) 
Age (years) 











Age group # (%):     
 
0.024 
   30≤years<55  17 (17%)  25 (26%)  42 (21%) 
   55≤years<69  55 (55%)  58 (59%)  113 (57%) 
   69 years and older  28 (28%)  15 (15%)  43 (22%) 
Never-smokers 













































Older than 26 years at 1



























































































Despite some differences between the LIDPBC and the 
NHANES samples with regard to race/ethnicity, age 
and lifestyle factors, the findings of both studies 
indicate an increased risk for breast cancer with 
increased body burden of cadmium, with similar effect 
















































registry-based sample from a geographic region with a 
relatively high incidence of breast cancer and from a 
cross-sectional, national probability sample support an 
association between environmental cadmium exposure 
and risk of  breast cancer, as initially reported in a non-
occupationally exposed group of women in Wisconsin
 
[11].  Since LIDPBC study is not probability-based, the 





 NHANES  (1999-2008)  LIDPBC  (2008-2009) 
UCd Quartiles  Odds ratio (95% CI)  p-value  Odds ratio (95% CI)  p-value 
I. Unadjusted model 
  99 cases + 3,120 non-cases  100 cases + 98 controls 
   Q1: UCd<0.22  1.00 (Reference)  -  1.00 (Reference)  - 
   Q2: 0.22≤UCd<0.37  1.85 (0.75, 4.56)  0.182  1.05 (0.33, 3.33)  0.940 
   Q3: 0.37≤UCd<0.60  3.84 (1.95, 7.55)  <0.001  2.27 (0.97, 5.33)  0.060 
   Q4: UCd≥0.60  3.39 (1.64, 7.05)  0.001  3.54 (1.49, 8.42)  0.004 
p-value for trend test  <0.001  0.001 
II. Age-adjusted model
a 
  99 cases + 3,120 non-cases  100 cases + 98 controls 
   Q1: UCd<0.22  1.00 (Reference)  -  1.00 (Reference)  - 
   Q2: 0.22≤UCd<0.37  1.48 (0.59, 3.69)  0.399  1.01 (0.31, 3.32)  0.982 
   Q3: 0.37≤UCd<0.60  2.62 (1.21, 5.69)  0.015  2.23 (0.94, 5.28)  0.068 
   Q4: UCd≥0.60  2.09 (0.87, 5.00)  0.098  3.29 (1.36, 7.99)  0.008 
p-value for trend test  0.039  0.004 
III. Multivariable model adjusting for common variables
b 
  92 cases + 2,884 non-cases  100 cases + 98 controls 
   Q1: UCd<0.22  1.00 (Reference)  -  1.00 (Reference)  - 
   Q2: 0.22≤UCd<0.37  1.34 (0.52, 3.45)  0.539  1.07 (0.31, 3.70)  0.910 
   Q3: 0.37≤UCd<0.60  2.50 (1.11, 5.63)  0.028  1.92 (0.77, 4.77)  0.162 
   Q4: UCd≥0.60  2.22 (0.89, 5.52)  0.086  2.69 (1.07, 6.78)  0.036 
p-value for trend test  0.039  0.023 
         Model III, also adjusting for race
c in NHANES and family history
d in LIDPBC  
Sample size:  92 cases + 2,884 non-cases  100 cases + 98 controls 
   Q1: UCd<0.22  1.00 (Reference)  -  1.00 (Reference)  - 
   Q2: 0.22≤UCd<0.37  1.38 (0.54, 3.53)  0.507  0.98 (0.28, 3.46)  0.979 
   Q3: 0.37≤UCd<0.60  2.56 (1.13, 5.78)  0.024  2.01 (0.80, 5.04)  0.139 
   Q4: UCd≥0.60  2.32 (0.92, 5.84)  0.074  2.81 (1.11, 7.13)  0.030 
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i.e., less than 1%
 (NYSDOH 2010), however, that the 
odds ratio can be used to estimate risk in our case-control 
study even though the control group is not a sample of 
the total population
 [28]. A sensitivity analysis using a 
dichotomous UCd variable (i.e., below and above 
median) based upon the UCd frequency distribution for 
LIDPBC controls showed similar results. 
 
To estimate the potential impact of cadmium body 
burden on breast cancer risk for the exposed LIDPBC 
sample, we calculated an attributable risk percent for 
individuals with UCd ≥0.37 μg/g (weighted median for 
NHANES sample) based upon relative risk estimated 
from cross-tabulated frequencies for exposure and breast 
cancer in the LIDPBC sample. Because causality has 
not been established, we use the term excess fraction 
[28]. Assuming no unmeasured confounding, the 
estimated percent excess fraction for breast cancer 
among women with UCd  ≥0.37 μg/g would be 43% for 
the LIDPBC sample.  To take into account the complex 
survey design of the NHANES sample, and because 
NHANES is representative of the US population, we 
calculated population excess fraction for US women 
using the weighted, multivariable-adjusted odds ratio as 
a proxy for relative risk, which is appropriate given the 
rare disease assumption, e.g., 1% or less disease 
prevalence [28]. Based on a multivariable model, with 
binary UCd exposure (using  a median cut) as a risk 
factor yielding a prevalence of 50%, the odds ratio was 
2.0. Again, assuming no unmeasured confounders, 35% 
of breast cancer prevalence among US women would be 
attributable to cadmium exposures greater than or equal 
to 0.37 ug/g (95% CI=16%, 56%), an estimate similar to 
the population attributable risk estimated by McElroy 
[11] in a regional population study, i.e., 45 of 124 
annual breast cancer cases per 100,000 women, or 36%. 
These estimates should be interpreted with caution, 
however, because the extent to which unmeasured 
confounders may have influenced results is uncertain. 
 
A limitation of the NHANES sample is lack of family 
history of breast cancer. Additionally, self-report of 
breast cancer diagnosis might introduce a 
misclassification bias not present in the LIDPBC 
sample. Renal dysfunction may be induced by cadmium 
exposure [29] and by chemotherapy [30] but whether 
renal dysfunction affects cadmium excretion is 
uncertain. To evaluate whether renal dysfunction may 
have confounded our analysis of the association of urine 
cadmium with breast cancer, we added a covariate for 
self-report of physician diagnosed renal impairment to 
the NHANES model. There were only 3 participants 
who reported both renal impairment and breast cancer 
and inclusion of this covariate generated similar effect 
estimates for the association.  
 
In the NHANES sample, the median difference between 
age at breast cancer diagnosis and age at UCd 
measurement was 7 years, and ranged from 5-12 years 
in the LIDPBC sample. Thus, women from both 
samples may have higher UCd levels than at the time 
they were diagnosed with breast cancer. To address a 
potential influence of incremental yearly age with 
regard to urine cadmium levels, a continuous variable 
for age in years was substituted for the categorical age 
group variable in each sample model, a continuous log-
transformed UCd variable was substituted for UCd 
quartiles, and tested for interaction. The LI model 
showed a statistically significant association between 
breast cancer and the log-transformed UCd (OR=1.81, 
95% CI=1.10, 2.96; p=0.019), but the interaction 
between age and UCd was not statistically significant 
and the model fit was adequate with main effects 
(Residual chi-square=0.655). The NHANES model, 
however, showed a statistically significant interaction 
(p=0.012). Stratification by median age (54 years) 
adjusted for year of age, showed that there was no 
significant association among women older than 54 years 
and significantly increased risk for women age 54 or 
younger in the third and fourth UCd quartiles (OR=6.35; 
95% CI=1.05, 38.29; p=0.044 and OR=7.25; 95% 
CI=1.04, 50.72; p=0.046; p-value for trend test=0.010). 
Confidence intervals were wide due to small sample size. 
McElroy [11] also found cadmium-associated risk for 
breast cancer in younger women. Larger longitudinal 
studies are needed to evaluate the effects of UCd 
exposures at different ages on breast cancer risk.   
 
The extent to which urine cadmium reflects long-term 
cadmium exposure may be influenced by age. Lauwerys 
[31] suggested that, at general environmental exposures, 
urinary cadmium levels parallel cadmium body burden 
until age 50-60 years but the extent to which recent 
exposures may also be reflected in urine cadmium 
among older general populations is uncertain. A 
possible limitation of both the NHANES and LIDPBC 
studies is the use of spot urine samples, which may 
constrain the accuracy of exposure assessment due to 
variable urinary dilution effects throughout the day [32]. 
Berlin [33], however, reported an excellent correlation 
between cadmium levels measured in spot and 24 hour 
samples from occupationally exposed subjects and spot 
urines have been used for numerous studies of lifetime 
cadmium exposure [34]. 
 
 Breast cancer phenotype is another unmeasured factor, 
as cadmium has been associated with basal breast cancer 
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breast cancer is more common in younger women [35]. 
The frequency of basal cell breast cancer is about 15%, 
however, making it unlikely that our data in either 
sample is skewed because of a preferential induction of 
this type of breast cancer. A relatively longer time lag 
between breast cancer diagnosis and UCd measurement 
among NHANES participants could result in loss of 
subjects due to breast cancer mortality and 
underestimation of  risk in that population. The cross-
sectional design of the NHANES analysis limits 
interpretations of causality but, because UCd is a 
biomarker of lifetime exposure
 [12]), it is reasonable to 
assume that exposure to cadmium occurred prior to 
breast cancer diagnosis.  
 
Although smoking is a well-established source of 
cadmium exposure, we found similar estimates for an 
association between increased UCd and breast cancer, 
independent of tobacco use in both samples, as was also 
reported by McElroy [11] in a Wisconsin regional 
sample. Additionally, in fully-adjusted Models III for 
NHANES and LIDPBC, the smoking covariate was not 
significantly associated with increased breast cancer 
risk in either sample. In consideration of cigarettes as a 
source of cadmium exposure, as well as inconsistent 
scientific findings regarding the association of breast 
cancer with smoking [36,37], we tested for interaction 
effects between smoking and the continuous cadmium 
exposure variable in multivariable analysis and the 
interaction term was not statistically significant in either 
the NHANES or the LIDPBC models.  
 
The reason that never-smoking LI residents with or 
without breast cancer participating in this study have 
significantly higher total body burdens of cadmium than 
non-smoking women in the US sample is not known.  
Furthermore, a larger population-based study of breast 
cancer as a function of cadmium body burden in long-
term residents of LI is needed to determine whether 
there is greater cadmium exposure in this region than in 
the US in general. If true, this could be a lead toward 
understanding at least one factor that may contribute to 
increased breast cancer risk in certain populations. 
 
The molecular mechanisms underlying the ability of 
cadmium to increase risk of specific cancers remain to be 
delineated. The fact that cadmium may directly lead to 
cellular transformation of breast cells to a cancer 
phenotype and also bind to and activate the estrogen 
receptor alpha, as well as accumulate in breast adipose 
tissue, as reported by Antila [38], are intriguing leads to 
its association with breast cancer risk.  Understanding the 
apparent multiple effects of cadmium is particularly 
challenging because of its ability to increase basal levels 
of oxidative DNA damage and to inhibit DNA repair [22, 
39, 40]. Thus, Schwerdtle [22] showed in vitro that both 
water soluble and particulate cadmium disrupt nucleotide 
excision repair of bulky DNA adducts and UVC-induce 
DNA photolesions, supporting the hypothesis that 
cadmium acts as an indirect genotoxic agent.  
 
The carcinogenic effects of cadmium could also be 
mediated in part by its ability to interfere with the 
function of p53, a key regulator of many components of 
DNA-damage induced defense mechanisms [41] and by 
its ability to substitute for zinc in proteins essential to 
cell integrity, such as XPA, an enzyme critical to 
nucleotide excision repair [42, 43]. Kopera [44] showed 
that a peptide synthesized to resemble the zinc-finger 
domain of human XPA had a 1000-fold higher binding 
constant for cadmium compared to zinc and Asmuss 
[45] demonstrated that cadmium impairment of DNA-
binding of purified XPA is reversed by zinc addition. 
 
In addition, cadmium alters a number of molecular 
pathways, which regulate cell development and growth 
including the E-cadherin/β-catenin complex and genes 
activated in response to mitogens such as c-fos, c-jun, 
and c-myc and/or are induced by stress [46, 47]. Chen 
[48] reported that cadmium induces multiple mitogen 
activated kinases and also activates mTOR, the 
mammalian target of rapamycin and that the clinically 
used drug rapamycin blocks cadmium-induced activity 
of mTOR, suppressing the cadmium-induced apoptosis 
of neural cell lines. Rapamycin has been shown to 
increase the lifespan of mice, mimicking the effect of 
caloric restriction, which is known to reduce mTOR 
activity and to increase the lifespan of many species. 
Anisimov [49] have recently shown that rapamycin 
increases lifespan and suppresses tumor development in 
cancer prone mice. Whether pharmacologic inter-
ventions to block or minimize the molecular actions of 
cadmium underlying its carcinogenic contributions are 
feasible are unknown but approachable challenges. 
 
Our findings, like those of McElroy et al (11), indicate 
increased risk for breast cancer associated with 
increased urine cadmium concentrations that is 
independent of tobacco use. Although smoking is a 
well-established source of cadmium exposure, the major 
route of cadmium exposure is ingestion of food, 
particularly root vegetables, potatoes, and grain, 
including rice and wheat, grown on cadmium rich soils, 
and shellfish (50-56). The estimated daily intake of 
cadmium in food in a non-hazardous environment for 
heavy metals is between 8 to 25 μg/day whereas one 
pack of cigarettes is estimated to add 1 μg/day
 [15, 55]. 
Recently, phosphate fertilizers were cited by the 
President’s Cancer Panel as a major source of cadmium 
   
www.impactaging.com                  810                                   AGING,    November 2010, Vol.2 No.11in the food supply [56]. Cadmium enters the soil through 
the application of cadmium containing chemical 
fertilizers, municipal sewage sludge, and contaminated 
irrigation water to agricultural fields and worldwide 
through atmospheric deposition from gases emitted from 
industry. Important sources of cadmium pollution are 
byproducts of welding, electroplating, zinc and lead 
mining, smelting, disposal of nickel/cadmium batteries, 
and the plastics and pigment industries [55-56].  
 
In addition to breast and other cancers [13, 57], there is 
considerable evidence that cadmium contributes 
significantly to several common serious diseases in 
addition to cancers including osteoporosis [58-64]; 
stroke and heart failure [65], and renal tubular damage 
[15, 34]. In 2009, the European Commission on 
Cadmium in Food lowered the permissible tolerable 
weekly intake of dietary cadmium from 7 ug/kg body 
weight (b.w.) per week to 2.5 ug/kg/ b.w. per week. 
This guideline was designed to keep the UCd below 1.0 
ug/g in 95% of the population by age 50 years [55]. The 
study of McElroy [11] and our present study, however, 
indicate that UCd below 1.0 ug/g is associated with 
increased risk of breast cancer.  
 
Further research is needed to evaluate the extent of risk 
that increasing environmental concentrations of 
cadmium pose for breast cancer and to identify specific 
sources of cadmium exposure, particularly in 
geographic areas with high breast cancer rates. 
Moreover, studies of the interplay between cadmium 
exposure via particular foodstuffs and gastrointestinal 
absorption
  (26) may provide insights as to ways to 
mitigate cadmium’s potential deleterious effects. At 
present, however, public health measures to reduce 
exposure to environmental cadmium including 1) 
decreasing fertilizer cadmium content; 2) informing the 
public about cadmium risks and identifying excessively 
rich cadmium foodstuffs; and, 3) minimizing release of 
cadmium from metal processing industries and 
electronic trash disposal is the first line of defense 




Ethics statement. This investigation has been conducted 
in accordance with the ethical standards and according 
to the Declaration of Helsinki and according to national 
and international guidelines and has been approved by 
the Committee on Research Involving Human Subjects 
at Stony Brook University, Stony Brook, NY, USA.  
  
Data for the case-control study of LI women were 
obtained from the LIDPBC comprised of 605 women, 
age 30 years or older, living on LI for, at least, 5 
consecutive years prior to entry on study, 373 of whom 
had histologically documented breast cancer diagnosed 
after January 1, 1998 through December 31, 2004 and 
232 women in the same region without a history of 
breast cancer. Cases in the LIDPBC had been identified 
through the cancer registry of Stony Brook University 
Hospital and contacted by their primary physicians to 
determine interest in participating. The control group 
was a purposive sample recruited from the community 
through local ads, presentations at health fairs, 
fundraisers for breast cancer research, and word of 
mouth, primarily through the breast cancer participants.  
Those providing informed consent completed a 
demographic, occupational, and health questionnaire 
under the supervision of a trained interviewer, including 
family history of breast cancer, use of hormone therapy 
other than birth control pills, age at first live birth, and 
menopausal status, provided a blood sample, and agreed 
to be contacted as to their interest in participating in 
future studies. For the present cadmium study, enrollees 
in the LIDPBC were invited to participate by mail. The 
first 100 women who had had breast cancer and the first 
100 women without breast cancer to agree to the study 
were selected. Participants completed an informed 
consent, which included permission to use their 
questionnaire information on file in the LIPDBC, and 
provided a single urine sample. From 2008-2009, urine 
was collected in a coded cadmium-free urine container 
and sent to ARUP Laboratories (Salt Lake City, UT) for 
measurement of urine cadmium by inductively coupled 
plasma-mass spectrometry (ICP-MS)
 and measurement 
of urine creatinine.   
    
Data were obtained from NHANES, a cross-sectional, 
random household survey of the civilian population 
based on a probability sampling design [66] for survey 
years 1999-2008.  All women age 30 years and older, 
whose urine cadmium concentration were measured in a 
single sample by ICP-MS at the Center for Disease 
Control (CDC) were initially included. Urine collection 
tubes and storage containers were pre-screened by the 
CDC for background contamination of cadmium (CDC 
2010). Analyses were then limited to women with UCd 
levels ≤20 ng/mL (unadjusted for urine creatinine), as 
recommended by Whittemore [67] to exclude 
observations with UCd levels beyond an upper bound 
for plausible values in environmental exposures. As a 
result, one participant without breast cancer diagnosis 
was excluded. Participants provided answers to a 
reproductive questionnaire, which included use of 
hormones other than birth control pills, age at first live 
birth, and menopausal status.  Breast cancer was 
determined by self-report of a physician diagnosis; 
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NHANES sample.  
 
The NHANES and LIDPBC study samples were 
summarized by unweighted descriptive statistics: 
medians, means (arithmetic and geometric) and 
standard deviations for continuous variables, and 
frequencies and proportions for categorical variables. 
Quartiles for creatinine-adjusted UCd were generated 
using weighted frequency distributions for the entire 
NHANES sample and used to evaluate the relationship 
between cadmium exposure and breast cancer in both 
the NHANES and LIDPBC samples. The quartiles 
were: 1
st quartile (Q1), UCd<0.22;  2
nd quartile (Q2), 
0.22≤UCd<0.37;  3
rd quartile (Q3), 0.37≤UCd≤0.60;  4
th 
quartile (Q4), UCd≥0.60. In addition, a dichotomous 
UCd variable, for values below and above the median 
UCd, was created for the LIDPBC sample using UCd 
frequency distributions for LIDPBC controls: 
UCd≤0.40 and UCd >0.40 μg/g. Three age groups were 
analyzed: 30-54; 55-68; and 69 and older. For the 
NHANES sample, Medical Examination Center 
subsample weights for participants with urine 
cadmium measurements and Taylor linearization 
methodology were used for analysis of the NHANES 
sample in accordance with complex survey design. For 
each variable in the two study samples, univariate 
logistic regression analysis was performed to evaluate 
its association with breast cancer status. The analyses 
were based on weighted data for NHANES sample and 
unweighted data for LIDPBC sample. For the LIDPBC 
sample, comparisons between the LIDPBC cases and 
controls were also made using two-sample t-tests for 
geometric mean of UCd and arithmetic mean of age, 
Mann-Whitney U-statistic for median of UCd, and 
Chi-square and Fisher’s exact tests (when applicable) 
for proportions, such as age group, smoking status, 
etc.  
 
To evaluate the association between urinary cadmium 
and breast cancer, a series of logistic regression models 
were fitted to each sample including an unadjusted 
logistic model, an age-group adjusted logistic model, 
and a common logistic model, which adjusted for the 
same set of variables in both samples, and excluded 
variables with a p value >0.15 in univariate logistic 
regression analysis with breast cancer in both datasets. 
A final multivariable logistic model incorporating 
dataset-specific information, i.e., breast cancer family 
history, was also explored for the LIDPBC data, and 
race/ethnicity was added to the final NHANES model. 
Interactive effects between UCd and major covariates in 
association with breast cancer were also considered. We 
conducted further analysis of the sample stratified by 
the covariate, if the interaction term had a p-value ≤ 
0.05. Odds ratios and their 95% confidence intervals 
(CI) were summarized. The linear association between 
UCd quartiles and breast cancer was analyzed by trend 
test. Models for complex survey design met the 
convergence criterion and case-control models met 
Hosmer-Lemeshow test for goodness of fit. Stata 
version 8.2 was used to perform t-tests. All other 
statistical analyses were performed using SAS version 
9.2. A two-sided p value of less than 0.05 was regarded 
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